Navigating Insurance Reimbursement in CIDP: Commercial Insurance
Join us as we explore the reimbursement process as it relates to CIDP. These engaging, interactive sessions are tailored to those with either Commercial Insurance or Medicare. Register for your program today! “Navigating Insurance Reimbursement in CIDP: Commercial Insurance” is live on Thursday, August 19, 2021, at 12:15 PM EDT. This session will explore the…
Medicare B will cover an immunoglobulin therapy for patients with CIDP, starting July 18, 2021
A message from our industry partners at CSL Behring: We are pleased to share that effective July 18, Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, will be covered under Medicare Part B for maintenance therapy in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).* Under the new coverage, Hizentra will be covered under the same benefit…
Live Webinar! CIDP: Improving Timely Diagnosis, Assessment, and Treatment (For Physicians Only)
Live Date: August 5, 2021 Time: 11:30am ET Program Expiration: August 5, 2022 While chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common of the acquired immune-mediated demyelinating neuropathies, it remains a challenge to differentiate it from other immune-mediated inflammatory conditions. Clinicians may also find it difficult to recognize atypical presentations of CIDP. These issues…
Live Webinar! Becoming Empowered with CIDP: Making My Voice Heard
We are pleased to announce a new, live video education session: “Becoming Empowered with CIDP: Making My Voice Heard” live on Thursday, August 5, 2021 at 10:00 AM ET. An expert panel of neurology and pharmacy clinicians, as well as a patient with CIDP, will discuss the disease and review the questions every patient should…
Tell Congress Why Plasma Is Essential
For many people, IVIG and SCIG is an amazing, life-saving medication! IVIG and SCIG are immunoglobulin therapies created from source plasma. Source plasma is donated from healthy volunteers at one of many plasma collection centers across the country. People who donate plasma are everyday heroes and we thank them for their time and contribution! Currently,…
Angela’s Adaptive Devices
Written by Angela Patton Angela Patton is a member of GBS|CIDP’s Advisory Committee. In 2017, after an eight months struggle for a proper diagnosis, Angela was diagnosed with CIDP. Here is Angela’s story… I was barely able to walk, and struggled during this time in my educational, and professional life. I have been on various…
FDA Warning for Guillain–Barre Syndrome and the Johnson & Johnson COVID-19 Vaccine
A Statement from the Foundation Global Medical Advisory Board The Washington Post and New York Times published on July 12, 2021 articles of a report by the FDA regarding cases of purported GBS after receiving the Johnson and Johnson COVID 19 vaccine. Approximately 100 reports of suspected GBS were experienced by 12.8 million subjects who…
Patients, Caregivers Connect for June Coffee Chat
Everyone has different ways of coping with GBS, CIDP and variants, and it can definitely be a struggle when you look completely healthy on the outside. Some people will certainly be judgmental at times, not understand the severity of the disease or even in some cases think that the person is exaggerating their symptoms. With…
In response to CBP preventing Mexican nationals from donating blood plasma
June 30, 2020 By Lisa Butler, Executive Director GBS|CIDP Foundation International Imagine the shock and helplessness of seeing your child’s body suddenly growing weak, clumsy, and unable to walk, or even stand; the fear that they may never live a normal life, or even survive this terrifying, disabling disorder. Imagine being greeted with the puzzlement…
An Update from the International Guillain-Barre Study (IGOS) by Dr. Bart Jacobs
The IGOS-1000 cohort has now been tested for the main preceding infections and is currently tested for antibodies extensively. We have also recently finalized a study in IGOS on the association between GBS and SARS-CoV-2 during the first 3 months of the pandemic. In my view this study shows the importance of having an ongoing…
NEW Bill in Congress Aims to Help Improve Access to Home Infusion IVIG for CIDP and MMN Patients, HR 3808
As a result of the community coming together this year, the Foundation is proud to share the wonderful news that our Congressional champions, led by Congressman Earl Blumenauer, Congressman G.K. Butterfield, and Congressman Chris Smith, have introduced a new bill that aims to help improve coverage of home infusion of IVIG for CIDP and MMN…
Christopher Cross Research Fund
CLICK HERE to Join Christopher Cross in Supporting Research
COVID-19 Vaccines and the GBS|CIDP Community
The GBS|CIDP Foundation has received many questions about COVID-19 and its relationship to Guillain-Barré syndrome and CIDP.
Information on Shingrix
The FDA is committed to safety and transparency for all Americans using any medicine. As a result of their commitment to safety and transparency, the FDA has decided to include GBS on information about the possible side effects of the Shingrix vaccine for shingles, given to older Americans. This safety warning ONLY applies to one…
Coping with School & Treatment Plan for GBS|CIDP
By Megan Kaump A diagnosis of GBS, CIDP, or variants is frightening and devastating for anyone, but when a child is diagnosed it adds a very different set of emotions and experiences. It is heart- breaking to see your child go through such challenges and there is the added component of how the child’s schooling…